Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UDCA as an adjuvant neuroprotective treatment in rhegmatogenous retinal detachment surgery
2023-505106-41-01Phase 3Authorised
- Sponsor
- Hôpital Foch
- Start
- Aug 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rhegmatogenous retinal detachment (RRD) comparing Ursolvan plus surgery with Placebo plus surgery (2 arms). Primary endpoint: Visual recovery at 3 months. Planned start Aug 2024; status: authorised.
02
Drugs
ursodeoxycholic acid
03
Conditions
rhegmatogenous retinal detachment (RRD)
Beyond the preview
Go deeper on 2023-505106-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505106-41-01.